Abbott Laboratories
ABT
102.53
-1.53
-1.47%
Abbott Laboratories
US · ABT
#113 by market cap
Listed 1970
102.53
-1.53
-1.47%
Live - 5344 symbols - heartbeat 140s ago
· 2026-10-20 15:40
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 9 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 81.08% -0.02pp
- Institutions
- 3,372 -9
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund65.44%
Public Company4.61%
Hedge Fund3.35%
Private Company2.97%
Government Pension Fund1.83%
Sovereign Wealth Fund1.41%
Family Office/Trust0.57%
Individual/Insider0.50%
Insurance Company0.31%
Other19.02%
Top holders as of 2026-06-30
BlackRock
8.82% · 152.56M sh
Vanguard Capital Management, LLC
7.14% · 123.53M sh
State Street Global Advisors
4.68% · 80.93M sh
Capital Research
4.21% · 72.87M sh
Charles Schwab Investment Management
3.45% · 59.70M sh
Other
71.71%
Vanguard Portfolio Management, LLC
2.83% · 49.02M sh
Geode Capital Management, LLC
2.27% · 39.22M sh
Norges Bank Investment Management
1.35% · 23.35M sh
T. Rowe Price Group, Inc.
1.33% · 23.06M sh
UBS Asset Management
1.17% · 20.19M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| Daniel Starks | Independent Director | 0.39% |
| Robert Ford | Chairperson & CEO | 0.03% |
| Robert Funck | Officer | 0.02% |
| Hubert Allen | General Counsel | 0.01% |
| Daniel Salvadori | Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 0.01% |
| Mary Moreland | Officer | 0.01% |
| Lisa Earnhardt | Executive Vice President of Medical Devices | 0.01% |
| Philip Boudreau | CFO & Senior VP of Finance | 0.00% |
| Kevin Conroy | Director | 0.00% |
| Andrea Wainer | Executive Vice President of Rapid & Molecular Diagnostics | 0.00% |
| Christopher Scoggins | Former Senior Vice President of Rapid Diagnostics | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | John Stratton | Independent Director | Other Derivative Acquisition | +397 | -- |
| 2026-09-29 | Kevin Conroy | Director | Other Derivative Acquisition | +318 | -- |
| 2026-09-29 | Michael Roman | Independent Director | Other Derivative Acquisition | +381 | -- |
| 2026-09-29 | Patricia Gonzalez | Independent Director | Other Derivative Acquisition | +333 | -- |
| 2026-09-29 | Nita Ahuja | Independent Director | Other Derivative Acquisition | +318 | -- |
| 2026-09-22 | Kevin Conroy | Director | Sale to Issuer | -52,507 | $103.99 |
| 2026-09-01 | John McCoy | VP of Finance & Controller | Open Market Disposition | -27 | $109.54 |
| 2026-08-31 | John McCoy | VP of Finance & Controller | Sale to Issuer | -52 | $110.36 |
| 2026-08-31 | Philip Boudreau | CFO & Executive VP of Finance | Sale to Issuer | -388 | $110.36 |
| 2026-08-24 | Robert Ford | Executive Chairperson | Derivative Exercise and Sale | -398,832 | $44.40–116.19 |
| 2026-08-11 | Louis Morrone | Executive Vice President of Core Diagnostics | Disposition Under Employee Benef | -12 | $107.99 |
| 2026-08-10 | Louis Morrone | Executive Vice President of Core Diagnostics | Open Market Disposition | -5,850 | $109.83 |
| 2026-06-29 | John Stratton | Independent Director | Other Derivative Acquisition | +432 | -- |
| 2026-06-29 | Kevin Conroy | Director | Other Derivative Acquisition | +231 | -- |
| 2026-06-29 | Michael Roman | Independent Director | Other Derivative Acquisition | +416 | -- |
| 2026-06-29 | Patricia Gonzalez | Independent Director | Other Derivative Acquisition | +363 | -- |
| 2026-06-29 | Louis Morrone | Executive Vice President of Core Diagnostics | Sale to Issuer | -269 | $92.71 |
| 2026-06-29 | Nita Ahuja | Independent Director | Other Derivative Acquisition | +347 | -- |
| 2026-06-26 | Elizabeth Cushman | General Counsel | Sale to Issuer | -560 | $94.12 |
| 2026-05-14 | Robert Alpern | Former Independent Director | Intent to Sell (Form 144) | -7,587 | $85.25 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-20 15:40:12 · For reference only, not investment advice and not tailored to your situation.
Abbott Laboratories discussion 0 comments